期刊
CLINICS IN LABORATORY MEDICINE
卷 31, 期 3, 页码 443-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cll.2011.07.001
关键词
Clinical proteomics; Multiplex; Multiple reaction monitoring mass spectrometry; In vitro diagnostics; Regulatory science
Clinical proteomics provides valuable information to the study of diseases at the molecular level, with the potential to discover biomarkers for disease states. The discovery of protein/peptide signatures leaked by cancerous tumors into clinically accessible fluids could possibly lead to developing quantitative assays for diagnosing cancer early. Despite having over 1,200 cancer-related protein biomarker candidates published in the scientific literature,(1) the rate of introduction of new protein biomarkers to market as approved by FDA has averaged 1.5 new proteins per year for 15 years. This discrepancy points to an ineffective translation of proteomics from the bench to the bedside.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据